Core Insights - Nanobiotix presented full results from a Phase 1 study of JNJ-1900 (NBTXR3) for locally advanced or borderline resectable pancreatic cancer at the 2025 ESTRO Annual Meeting [1][3] - The study showed promising safety and efficacy outcomes, indicating a potential new treatment option for patients with high unmet needs in this area [5][9] Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on innovative nanotherapeutic approaches to enhance cancer treatment outcomes [15][16] - The company is headquartered in Paris, France, and is listed on Euronext Paris and NASDAQ [16] Study Details - The Phase 1 study evaluated JNJ-1900 (NBTXR3) activated by radiotherapy in patients with locally advanced or borderline resectable pancreatic cancer, replacing standard concurrent chemoradiation [3][6] - The study was conducted by The University of Texas MD Anderson Cancer Center, with Dr. Eugene Koay as the principal investigator [1][3] Key Results - The study involved 22 patients, with a median overall survival of 23 months from diagnosis and a median local progression-free survival of 13.3 months from completion of radiation [5][6] - Notable findings included a 59% normalization rate of CA19-9, a biomarker associated with overall survival, and an association between increased circulating tumor mutational burden (cTMB) and improved survival outcomes [5][12] Future Directions - Investigators concluded that further evaluation of JNJ-1900 (NBTXR3) is warranted in a randomized study, with ongoing recruitment for a new cohort combining JNJ-1900 with standard-of-care concurrent chemotherapy [8][9] - The collaboration with MD Anderson aims to explore innovative treatment approaches for patients with high unmet needs in pancreatic cancer [9][14]